Hinderer
Christian Hinderer, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20150230430 | VETERINARY COMPOSITION AND METHODS FOR NON-SURGICAL NEUTERING AND CASTRATION - A method for non-surgical neutering or castration of a non-human mammal for AAV-mediated delivery of an anti-GnRH polypeptide to a non-human animal is described. More particularly, the animal is administered an adeno-associated virus (AAV) vector having an AAV capsid having packaged therein nucleic acid sequences comprising an AAV 5′ inverted terminal repeat (ITR), a sequence encoding a polypeptide which specifically binds gonadotropin releasing hormone (GnRH) under control of regulatory sequences which direct expression of the polypeptide, and an AAV 3′ ITR. A composition comprising the AAV-anti-GnRH may also be used for inhibiting tumor growth in a mammal with a cancer responsive to gonadal steroid hormones. | 08-20-2015 |
Joerg Hinderer, Waldshut-Tiengen DE
Patent application number | Description | Published |
---|---|---|
20130008187 | Cryostat configuration - A cryostat configuration with a vacuum vessel ( | 01-10-2013 |
20150084632 | DNP Apparatus - A DNP apparatus includes a cryostat ( | 03-26-2015 |
Karl Hinderer, Fichtenberg DE
Patent application number | Description | Published |
---|---|---|
20090001644 | Relocating Device Having at Least One Pilot Pin - A relocating device for a flexible processing line is embodied for relocating a workpiece holder ( | 01-01-2009 |
20090010739 | Processing Station for a Processing Line having a Module Platform and Withdrawable Modules that can be Introduced into the Module Platform - A processing station for a processing line, having a module platform ( | 01-08-2009 |
20130126307 | CONVEYING DEVICE - A conveying device for moving a carrying plate includes a pulling mechanism in the form of a belt. To pull the carrying plate, the belt is contacted against the carrying plate via a magnetic force of at least one permanent magnet. The carrying plate is then entrained by the belt as a result of static friction or sliding friction. | 05-23-2013 |
Mario Hinderer, Fichtenberg Ot Langert DE
Patent application number | Description | Published |
---|---|---|
20110068570 | CLAMPING COMPONENT COMPRISING A CUTTING ELEMENT FOR ESTABLISHING AN ELECTRICALLY CONDUCTIVE CONNECTION - A clamping component composed of metal and used to clamp a profiled element composed of metal has at least one clamping surface adapted to the profiled element, at least one cutting element which includes a cutting edge that extends beyond the clamping surface, thereby enabling the cutting element to penetrate the profiled element when the clamping component clamps the profiled element; and an engagement element for introducing a clamping force, wherein the cutting edge is situated at a slant and/or curve relative to the clamping surface such that the cutting edge initially touches the profiled element in a punctiform manner while the clamping part is clamped tightly, and an increasing region of the cutting edge subsequently penetrates the profiled element. | 03-24-2011 |
Robert Hinderer, Flint, MI US
Patent application number | Description | Published |
---|---|---|
20100330587 | Annexin Proteins and Autoantibodies As Serum Markers For Cancer - The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer. | 12-30-2010 |
Robert Hinderer, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20130177927 | Protein markers for esophageal cancer - Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from esophageal tumors, reveals proteins which are different in tumor and control tissue. | 07-11-2013 |
Thorsten Hinderer, Unterhaching DE
Patent application number | Description | Published |
---|---|---|
20150185759 | SYNCHRONIZATION OF A DATA SIGNAL - A method for synchronizing a data signal in a bus environment is suggested, the method may include providing multiple clock phases based on a reference oscillator; determining a phase out of the multiple clock phases for a transition of a data signal; and synchronizing the data signal based on the phase determined. | 07-02-2015 |
Walter Hinderer, Rogau DE
Patent application number | Description | Published |
---|---|---|
20100216698 | LIQUID FORMULATIONS OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 08-26-2010 |
Walter Hinderer, Rodgau DE
Patent application number | Description | Published |
---|---|---|
20090143292 | Liquid Formulation of G-CSF Conjugate - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 06-04-2009 |
20110053844 | LIQUID FORMULATION OF G-CSF CONJUGATE - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 03-03-2011 |
20120264688 | PROCESS FOR THE PURIFICATION OF RECOMBINANT HUMAN ERYTHROPOIETIN (EPO), EPO THUS PURIFIED AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - A procedure for the production of erythropoietin (EPO), in particular recombinant human EPO (rhEPO) with a defined composition of glycoforms in a highly pure form, i.e., with a high amount of O-glycosylated EPO isoforms is provided. | 10-18-2012 |
20120328560 | METHOD FOR OBTAINING BIOLOGICALLY ACTIVE RECOMBINANT HUMAN G-CSF - Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity. | 12-27-2012 |
20140030214 | LIQUID FORMULATION OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 01-30-2014 |
20150125420 | LIQUID FORMULATION OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 05-07-2015 |